Patents by Inventor George Mulligan

George Mulligan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH PROTEASOME INHIBITION THERAPY
    Publication number: 20170023577
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: March 25, 2016
    Publication date: January 26, 2017
    Inventors: George Mulligan, Barbara M. Bryant, Michael P. Morrissey, Andrew Bolt, Andrew I. Damokosh
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Patent number: 9500656
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are expected to demonstrate long term or short term survival times. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with expected short term or long term survival. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine predicted patient survival.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: November 22, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George Mulligan
  • METHODS FOR THE IDENTIFICATION, ASSESSMENT, AND TREATMENT OF PATIENTS WITH CANCER THERAPY
    Publication number: 20130013334
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: August 31, 2012
    Publication date: January 10, 2013
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George Mulligan
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Patent number: 8278038
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Grant
    Filed: June 8, 2006
    Date of Patent: October 2, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Barbara M. Bryant, Andrew I. Damokosh, George Mulligan
  • Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
    Publication number: 20090181393
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: December 16, 2008
    Publication date: July 16, 2009
    Inventors: George Mulligan, Barbara M. Bryant, Michael P. Morrissey, Andrew Bolt, Andrew I. Damokosh
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Publication number: 20080064055
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are expected to demonstrate long term or short term survival times. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with expected short term or long term survival. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine predicted patient survival.
    Type: Application
    Filed: August 9, 2007
    Publication date: March 13, 2008
    Inventors: Barbara Bryant, Andrew Damokosh, George Mulligan
  • Methods for the identification, assessment, and treatment of patients with cancer therapy
    Publication number: 20060281122
    Abstract: The present invention is directed to the identification of predictive markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain individual and/or combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen. Thus, by examining the expression levels of individual predictive markers and/or predictive markers comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: June 8, 2006
    Publication date: December 14, 2006
    Inventors: Barbara Bryant, Andrew Damokosh, George Mulligan
  • Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
    Publication number: 20040156854
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.
    Type: Application
    Filed: December 4, 2003
    Publication date: August 12, 2004
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: George Mulligan, Barbara M. Bryant, Michael P. Morrissey, Andrew Bolt, Andrew I. Damokosh